Sandeep Kumar1, Rafi Ahmed Jan2, Bashir Ahmad Fomda3, Roohi Rasool4, Parvaiz Koul1, Sonaullah Shah1, Umar Hafiz Khan1, Syed Mudasir Qadri1, Shariq Rashid Masoodi5, Suhail Mantoo1, Mudasir Muzamil1. 1. Department of Internal Medicine (Pulmonary Medicine), Sher I Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, 190001, India. 2. Department of Internal Medicine (Pulmonary Medicine), Sher I Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, 190001, India. rafiahmedjan@gmail.com. 3. Department of Microbiology, Sher I Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, 190001, India. 4. Department of Immunology and Molecular Biology, Sher I Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, 190001, India. 5. Department of Endocrinology, Sher I Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, 190001, India.
Abstract
BACKGROUND: Data regarding the comparative profiling of HCAP and HAP from developing countries like India are scant. We set out to address the microbial aetiology, antibiotic resistance and treatment outcomes in patients with HCAP and HAP. METHODS: 318 consenting patients with HCAP (n = 165, aged 16-90 years; median 60 years; 97 males) or HAP (n = 153; aged 16-85 years; median 45 years; 92 males) presenting to a tertiary care hospital in North India from 2013 to 2015 were prospectively recruited for the study. Data on patient characteristics, microbial aetiology, APACHE II scores, treatment outcomes and mortality were studied. Clinical outcomes were compared with various possible predictors employing logistic regression analysis. RESULTS: Patients in HCAP had more comorbidity. Escherichia coli (30, 18%) and Acinetobacter baumannii (62, 41%) were the most commonly isolated bacteria in HCAP and HAP, respectively. Multidrug-resistant bacteria were isolated more frequently in HCAP, only because the incidence of extensively drug-resistant bacteria was markedly high in HAP (p = 0.00). The mean APACHE II score was lower in HCAP (17.55 ± 6.406, range 30) compared to HAP (19.74 ± 8.843, range 37; p = 0.013). The length of stay ≥ 5 days (p = 0.036) and in-hospital mortality was higher in HAP group (p = 0.002). The most reliable predictors of in-hospital mortality in HCAP and HAP were APACHE II score ≥ 17 (OR = 14, p = 0.00; HAP: OR = 10.8, p = 0.00), and septic shock (OR = 4.5, p = 0.00; HAP: OR = 6.9, p = 0.00). CONCLUSION: The patient characteristics in HCAP, treatment outcomes, bacterial aetiology, and a higher incidence of antibiotic-resistant bacteria, suggest that HCAP although not as severe as HAP, can be grouped as a separate third entity.
BACKGROUND: Data regarding the comparative profiling of HCAP and HAP from developing countries like India are scant. We set out to address the microbial aetiology, antibiotic resistance and treatment outcomes in patients with HCAP and HAP. METHODS: 318 consenting patients with HCAP (n = 165, aged 16-90 years; median 60 years; 97 males) or HAP (n = 153; aged 16-85 years; median 45 years; 92 males) presenting to a tertiary care hospital in North India from 2013 to 2015 were prospectively recruited for the study. Data on patient characteristics, microbial aetiology, APACHE II scores, treatment outcomes and mortality were studied. Clinical outcomes were compared with various possible predictors employing logistic regression analysis. RESULTS:Patients in HCAP had more comorbidity. Escherichia coli (30, 18%) and Acinetobacter baumannii (62, 41%) were the most commonly isolated bacteria in HCAP and HAP, respectively. Multidrug-resistant bacteria were isolated more frequently in HCAP, only because the incidence of extensively drug-resistant bacteria was markedly high in HAP (p = 0.00). The mean APACHE II score was lower in HCAP (17.55 ± 6.406, range 30) compared to HAP (19.74 ± 8.843, range 37; p = 0.013). The length of stay ≥ 5 days (p = 0.036) and in-hospital mortality was higher in HAP group (p = 0.002). The most reliable predictors of in-hospital mortality in HCAP and HAP were APACHE II score ≥ 17 (OR = 14, p = 0.00; HAP: OR = 10.8, p = 0.00), and septic shock (OR = 4.5, p = 0.00; HAP: OR = 6.9, p = 0.00). CONCLUSION: The patient characteristics in HCAP, treatment outcomes, bacterial aetiology, and a higher incidence of antibiotic-resistant bacteria, suggest that HCAP although not as severe as HAP, can be grouped as a separate third entity.
Authors: Shelley S Magill; Michael Klompas; Robert Balk; Suzanne M Burns; Clifford S Deutschman; Daniel Diekema; Scott Fridkin; Linda Greene; Alice Guh; David Gutterman; Beth Hammer; David Henderson; Dean Hess; Nicholas S Hill; Teresa Horan; Marin Kollef; Mitchell Levy; Edward Septimus; Carole Vanantwerpen; Don Wright; Pamela Lipsett Journal: Clin Infect Dis Date: 2013-12 Impact factor: 9.079
Authors: June H Ahn; Kwan H Lee; Jin H Chung; Kyeong-Cheol Shin; Choong K Lee; Hyun Jung Kim; Eun Young Choi Journal: Medicine (Baltimore) Date: 2017-10 Impact factor: 1.889
Authors: Naomi J Gadsby; Clark D Russell; Martin P McHugh; Harriet Mark; Andrew Conway Morris; Ian F Laurenson; Adam T Hill; Kate E Templeton Journal: Clin Infect Dis Date: 2016-01-07 Impact factor: 9.079
Authors: Ana Lopez-de-Andres; Marta Lopez-Herranz; Valentin Hernandez-Barrera; Javier de-Miguel-Diez; Jose M de-Miguel-Yanes; David Carabantes-Alarcon; Romana Albaladejo-Vicente; Rosa Villanueva-Orbaiz; Rodrigo Jimenez-Garcia Journal: Int J Environ Res Public Health Date: 2021-11-30 Impact factor: 3.390